米国のマイナーカンナビノイドの市場規模、シェア、動向分析レポート：製品タイプ別、用途別、セグメント別予測、2024年～2030年

米国のマイナーカンナビノイド市場の成長と動向：

Grand View Research社の最新調査によると、米国のマイナーカンナビノイド市場規模は2030年までに333億米ドルに達する見込みです。

同市場は2024年から2030年にかけてCAGR 15.0％で拡大する見込みです。カンナビノイドベースの製品の使用の増加と、カンナビノイドの消費に関連する健康上の利点に関する意識は、成長を支える重要な要因の一部です。

マイナーカンナビノイドには、抗炎症作用、鎮痛作用、神経保護作用などの潜在的な治療効果があります。慢性疼痛、不安、睡眠障害など様々な病状の治療のために、マイナーカンナビノイドを含む医薬品や栄養補助食品の開発に関心が高まっています。例えば、2021年1月、Lygos, Inc.は、抗炎症作用、抗酸化作用、疼痛管理作用など幅広い効能を持つカンナビクロメン（CBC）の商業利用を発表しました。

サプリメント、チンキ剤、外用剤などのウェルネス製品には、マイナーカンナビノイドが配合されています。これらの製品は、さまざまな健康問題に対する自然療法として販売されており、従来の薬に代わるものを求める消費者の間で人気を集めています。例えば、パーソナルケアとヘルス＆ウェルネス製品のサプライヤーであるネクストラクション社は、カンナビノール（CBN）、カンナビジオール酸（CBDA）、カンナビゲロール酸（CBGA）を配合したクリバ（Kriva）シリーズを、外用剤と摂取可能な処方で発売しました。

米国のマイナーカンナビノイド産業におけるビジネスチャンスと足跡を強化するために主要企業が行う有機的・無機的な様々な発展は、予測期間中の市場拡大を促進すると予想されます。2022年10月、バイオテクノロジー企業であるPurissima, Inc.は、Open Book Extracts（OBX）と提携し、グミ、局所用美容液、チンキ剤、カプセルなどの初の発酵由来の天然CBC製品を発売しました。

米国のマイナーカンナビノイド市場レポートハイライト：

• 製品タイプ別では、テトラヒドロカンナビバリン（THCV）分野が2023年に25.9％の売上高シェアで市場を独占しました。これは、関節炎、代謝障害、てんかんなどの疾患の管理におけるTHCVの応用が増加しているためです。
• 用途別では、神経疾患の有病率の上昇とその管理におけるカンナビノイドの用途により、神経疾患分野が2023年に大きな収益シェアを占めました。
• 主な市場プレイヤー：GCM Holdings（Global Cannabinoids）, LLC、GenCanna、Mile High Labs、ZERO POINT EXTRACTION, LLC、BulKanna、CBD.INC.

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国のマイナーカンナビノイド市場：変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 米国のマイナーカンナビノイド市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 米国のマイナーカンナビノイド市場：製品タイプの推定・動向分析

• 製品タイプの市場シェア、2023年および2030年
• セグメントダッシュボード
• 製品タイプ別の米国のマイナーカンナビノイド市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第5章 米国のマイナーカンナビノイド市場：用途の推定・動向分析

• 用途の市場シェア、2023年と2030年
• セグメントダッシュボード
• 用途別の米国のマイナーカンナビノイド市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第6章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
• ベンダー情勢
  • Mile High Labs
  • GCM Holdings, LLC
  • GenCanna.
  • CBD. INC.
  • Rhizo Sciences
  • Laurelcrest
  • Fresh Bros Hemp Company
  • BulKanna
  • High Purity Natural Products
  • ZERO POINT EXTRACTION, LLC

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. minor cannabinoids market, by product type, 2018 - 2030 (USD Million)
• Table 3 U.S. minor cannabinoids market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. minor cannabinoids market: market outlook
• Fig. 9 U.S. minor cannabinoids competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 U.S. minor cannabinoids market driver impact
• Fig. 15 U.S. minor cannabinoids market restraint impact
• Fig. 16 U.S. minor cannabinoids market strategic initiatives analysis
• Fig. 17 U.S. minor cannabinoids market: Product type movement analysis
• Fig. 18 U.S. minor cannabinoids market: Product type outlook and key takeaways
• Fig. 19 Cannabigerol (CBG)market estimates and forecast, 2018 - 2030
• Fig. 20 Cannabichromene (CBC) market estimates and forecast, 2018 - 2030
• Fig. 21 Cannabinol (CBN) market estimates market and forecast, 2018 - 2030
• Fig. 22 Tetrahydrocannabivarin (THCV) market estimates and forecast, 2018 - 2030
• Fig. 23 Cannabigerolic acid (CBGA) market estimates and forecast, 2018 - 2030
• Fig. 24 Others (Cannabidiolic Acid (CBDA), Cannabidivarin (CBDV), And Other Minor Cannabinoids) estimates and forecast, 2018 - 2030
• Fig. 25 U.S. minor cannabinoids market: Application movement Analysis
• Fig. 26 U.S. minor cannabinoids market: Application outlook and key takeaways
• Fig. 27 Inflammation market estimates and forecasts, 2018 - 2030
• Fig. 28 Pain management market estimates and forecasts, 2018 - 2030
• Fig. 29 Neurological disorders market estimates and forecasts,2 018 - 2030
• Fig. 30 Cancer market estimates and forecasts, 2018 - 2030
• Fig. 31 Others market estimates and forecasts, 2018 - 2030

U.S. Minor Cannabinoids Market Growth & Trends:

The U.S. minor cannabinoids market size is expected to reach USD 33.3 billion by 2030, according to a new study by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.0% from 2024 to 2030. Rising use of cannabinoid-based products and awareness regarding the health benefits associated with cannabinoid consumption are some of the crucial factors supporting the growth.

Minor cannabinoids have potential therapeutic benefits, including anti-inflammatory, analgesic, and neuroprotective effects. There is a growing interest in developing pharmaceuticals and nutraceuticals containing minor cannabinoids for the treatment of various medical conditions, such as chronic pain, anxiety, and sleep disorders. For instance, in January 2021, Lygos, Inc. announced the commercial availability of cannabichromene (CBC) that has a wide range of anti-inflammatory, antioxidant, and pain management properties.

Wellness products such as supplements, tinctures, and topicals incorporate minor cannabinoids. These products are marketed as natural remedies for various health issues, and are becoming popular among consumers who are looking for alternatives to traditional medications. For instance, Nextraction, a supplier of personal care and health & wellness products, launched Kriva-a range of Cannabinol (CBN), cannabidiol acid (CBDA), and Cannabigerolic acid (CBGA)-in topical and ingestible formulas.

Various organic and inorganic developments done by key players to strengthen their business avenues and footprints in the U.S. minor cannabinoids industry are anticipated to facilitate market expansion over the forecast period. In October 2022, Purissima, Inc., a biotechnology company in partnership with Open Book Extracts (OBX), launched its first fermentation-derived natural CBC products such as gummies, topical serums, tinctures, and capsules.

U.S. Minor Cannabinoids Market Report Highlights:

• Based on product type, the tetrahydrocannabivarin (THCV) segment dominated the market with a revenue share of 25.9% in 2023, owing to increasing application of THCV in the management of conditions such as arthritis, metabolic disorders, and epilepsy
• Based on application, the neurological disorders segment accounted for a significant revenue share in 2023, due to the rising prevalence of neurological disorders and applications of cannabinoids in their management
• Some of the major market players include GCM Holdings (Global Cannabinoids), LLC, GenCanna, Mile High Labs, ZERO POINT EXTRACTION, LLC, BulKanna, and CBD. INC.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Application
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product type outlook
  • 2.2.2. Application outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Minor Cannabinoids Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Minor Cannabinoids Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Minor Cannabinoids Market: Product Type Estimates & Trend Analysis

• 4.1. Product Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. Minor Cannabinoids Market by Product Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Cannabigerol (CBG)
    • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Cannabichromene (CBC)
    • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Cannabinol (CBN)
    • 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Tetrahydrocannabivarin (THCV)
    • 4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Cannabigerolic acid (CBGA)
    • 4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Minor Cannabinoids Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global U.S. Minor Cannabinoids Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Inflammation
    • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. Pain Management
    • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. Neurological Disorders
    • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.4. Cancer
    • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.5. Others
    • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. Mile High Labs
    • 6.3.1.1. Company overview
    • 6.3.1.2. Financial performance
    • 6.3.1.3. Product benchmarking
    • 6.3.1.4. Strategic initiatives
  • 6.3.2. GCM Holdings, LLC
    • 6.3.2.1. Company overview
    • 6.3.2.2. Financial performance
    • 6.3.2.3. Product benchmarking
    • 6.3.2.4. Strategic initiatives
  • 6.3.3. GenCanna.
    • 6.3.3.1. Company overview
    • 6.3.3.2. Financial performance
    • 6.3.3.3. Product benchmarking
    • 6.3.3.4. Strategic initiatives
  • 6.3.4. CBD. INC.
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Product benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. Rhizo Sciences
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Product benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. Laurelcrest
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Product benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Fresh Bros Hemp Company
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Product benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. BulKanna
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Product benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. High Purity Natural Products
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Product benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. ZERO POINT EXTRACTION, LLC
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Product benchmarking
    • 6.3.10.4. Strategic initiatives